Benjamin Dälken

634 total citations
12 papers, 228 citations indexed

About

Benjamin Dälken is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Benjamin Dälken has authored 12 papers receiving a total of 228 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Immunology. Recurrent topics in Benjamin Dälken's work include Monoclonal and Polyclonal Antibodies Research (5 papers), Cell death mechanisms and regulation (3 papers) and HER2/EGFR in Cancer Research (2 papers). Benjamin Dälken is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (5 papers), Cell death mechanisms and regulation (3 papers) and HER2/EGFR in Cancer Research (2 papers). Benjamin Dälken collaborates with scholars based in Germany, Poland and Ivory Coast. Benjamin Dälken's co-authors include Winfried S. Wels, Shirley K. Knauer, Jörg Schüttrumpf, Martin König, Faı̈za Rharbaoui, Silke Aigner, Pranav Oberoi, Robert A. Jabulowsky, Hayat Bähr-Mahmud and Itai Benhar and has published in prestigious journals such as PLoS ONE, Cancer Research and Biochemical Journal.

In The Last Decade

Benjamin Dälken

12 papers receiving 227 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Benjamin Dälken Germany 9 108 101 57 46 32 12 228
Garrison C. Fathman United States 5 306 2.8× 76 0.8× 52 0.9× 26 0.6× 75 2.3× 8 377
Stefania Carrara Germany 10 62 0.6× 126 1.2× 108 1.9× 91 2.0× 27 0.8× 30 317
Anna Vaisman‐Mentesh Israel 6 119 1.1× 92 0.9× 123 2.2× 40 0.9× 20 0.6× 8 260
Denice T. Y. Chan United Kingdom 3 84 0.8× 68 0.7× 11 0.2× 25 0.5× 15 0.5× 4 181
Adam Bates United States 6 35 0.3× 129 1.3× 107 1.9× 39 0.8× 15 0.5× 8 229
AeRyon Kim United States 8 148 1.4× 94 0.9× 55 1.0× 35 0.8× 11 0.3× 14 262
Natko Nuber Switzerland 10 204 1.9× 106 1.0× 30 0.5× 152 3.3× 22 0.7× 13 311
Navreet K. Nanda United States 9 317 2.9× 133 1.3× 89 1.6× 84 1.8× 22 0.7× 15 390
KL Pogue-Geile United States 8 82 0.8× 233 2.3× 41 0.7× 75 1.6× 55 1.7× 14 371
Angela Seelig Germany 10 232 2.1× 340 3.4× 24 0.4× 162 3.5× 44 1.4× 11 504

Countries citing papers authored by Benjamin Dälken

Since Specialization
Citations

This map shows the geographic impact of Benjamin Dälken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Dälken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Dälken more than expected).

Fields of papers citing papers by Benjamin Dälken

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Dälken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Dälken. The network helps show where Benjamin Dälken may publish in the future.

Co-authorship network of co-authors of Benjamin Dälken

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Dälken. A scholar is included among the top collaborators of Benjamin Dälken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Dälken. Benjamin Dälken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
Vollenhoven, Ronald van, Edward Keystone, Vibeke Strand, et al.. (2018). Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial. Annals of the Rheumatic Diseases. 77(4). 495–499. 9 indexed citations
3.
Heim, Katharina, Benjamin Dälken, Faı̈za Rharbaoui, et al.. (2016). High thioredoxin‐1 levels in rheumatoid arthritis patients diminish binding and signalling of the monoclonal antibody Tregalizumab. Clinical & Translational Immunology. 5(12). e121–e121. 6 indexed citations
4.
König, Martin, Faı̈za Rharbaoui, Silke Aigner, Benjamin Dälken, & Jörg Schüttrumpf. (2016). Tregalizumab – A Monoclonal Antibody to Target Regulatory T Cells. Frontiers in Immunology. 7. 32 indexed citations
5.
König, Martin, Benjamin Dälken, André Engling, et al.. (2014). A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunology and Cell Biology. 93(4). 396–405. 29 indexed citations
6.
Jabulowsky, Robert A., Pranav Oberoi, Hayat Bähr-Mahmud, Benjamin Dälken, & Winfried S. Wels. (2012). Surface Charge-Modification Prevents Sequestration and Enhances Tumor-Cell Specificity of a Recombinant Granzyme B–TGFα Fusion Protein. Bioconjugate Chemistry. 23(8). 1567–1576. 13 indexed citations
7.
Dälken, Benjamin, Robert A. Jabulowsky, Pranav Oberoi, Itai Benhar, & Winfried S. Wels. (2010). Maltose-Binding Protein Enhances Secretion of Recombinant Human Granzyme B Accompanied by In Vivo Processing of a Precursor MBP Fusion Protein. PLoS ONE. 5(12). e14404–e14404. 15 indexed citations
8.
Zuber, Chantal, Benjamin Dälken, Silke Aigner, et al.. (2010). 226 High in vivo anti-tumor activity of the immunoconjugate BT-062 against CD138 positive solid tumors. European Journal of Cancer Supplements. 8(7). 74–74. 1 indexed citations
9.
Dälken, Benjamin, et al.. (2009). Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor. Molecular Cancer Therapeutics. 8(6). 1526–1535. 28 indexed citations
10.
Dälken, Benjamin, et al.. (2006). Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying EGFR- and ErbB2/HER2-specific binding domains for tumor cell recognition. Cancer Research. 66. 521–521. 1 indexed citations
11.
Dälken, Benjamin, et al.. (2006). Cell binding, internalization and cytotoxic activity of human granzyme B expressed in the yeastPichia pastoris. Biochemical Journal. 394(3). 563–573. 19 indexed citations
12.
Dälken, Benjamin, et al.. (2005). Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition. Cell Death and Differentiation. 13(4). 576–585. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Garrison C. Fathman Breakdown of academic impact, for papers by Stefania Carrara Breakdown of academic impact, for papers by Anna Vaisman‐Mentesh Breakdown of academic impact, for papers by Denice T. Y. Chan Breakdown of academic impact, for papers by Adam Bates Breakdown of academic impact, for papers by AeRyon Kim Breakdown of academic impact, for papers by Natko Nuber Breakdown of academic impact, for papers by Navreet K. Nanda Breakdown of academic impact, for papers by KL Pogue-Geile Breakdown of academic impact, for papers by Angela Seelig
Rankless by CCL
2026